AI assistant
Monopar Therapeutics — Director's Dealing 2023
Jan 3, 2023
32883_dirs_2023-01-03_0c87887f-510a-4e3e-b865-a64154a1ca69.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-12-31
Reporting Person: Cittadine Andrew (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Common Stock | M | 4062 | — | Acquired | 28300 | Direct |
| 2022-12-31 | Common Stock | F | 1406 | $2.37 | Disposed | 26894 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | Restricted Stock Units | $ | M | 4062 | Disposed | Common Stock (4062) | Direct |
Footnotes
F1: Represents shares acquired on vesting and settlement of restricted stock units.
F2: On February 2, 2022, the reporting person was granted 65,000 restricted stock units, vesting 6/48ths (8,125 shares) on June 30, 2022, and 3/48ths (4,063 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.